From: http://www.blogigo.com/timephram

The field of medicine as an important fine chemical industry has become over the past decade the focus of development and competitiveness, with the progress of science and technology, many Chinese medicine has been continuously developed for the benefit of humanity, these Chinese medicine relies on new synthesis of high-quality the production of pharmaceutical intermediates , new drugs are patent-protected, and not compatible with the existence of intermediate problems, so the new pharmaceutical intermediates and application of domestic and foreign markets are very optimistic about the prospects. Many new varieties of pharmaceutical intermediates, can not be fully introduced, this paper began to study in Taiwan in recent years, great concern a new type of pharmaceutical intermediates and pharmaceutical intermediates for a number of important new technology.

For example: 2-Chloro-4, 6-Dimethoxy-1, 3, 5-Triazine  CAS:3140-73-6 

 
Description: 2-Chloro-4, 6-Dimethoxy-1, 3, 5-Triazine
Synonym: CDMT
CAS: 3140-73-6
Assay:  ≥99% (GC)
Appearance: white crystalline powder
Molecular: C5H6ClN3O2
Application: Anti-neoplastic as pharmaceutical intermediates

http://www.timepharm.com/category/pharmaceutical-intermediates-2087-d2ac/1Antibody tests may give false negative (no antibodies were detected despite HIV being present) results during the window period, an interval of three weeks to six months between the time of HIV infection and the production of measurable antibodies to HIV seroconversion. Most people develop detectable antibodies approximately 30 days after infection, although some seroconvert later. The vast majority of people (99%) have detectable antibodies by three months after HIV infection; a six-month window is extremely rare with modern antibody testing. During the window period, an infected person can transmit HIV to others although their HIV infection may not be detectable with an antibody test. Antiretroviral therapy during the window period can delay the formation of antibodies and extend the window period beyond 12 months. This was not the case with patients that underwent treatment with post exposure prophylaxis (PEP). Those patients must take ELISA tests at various intervals after the usual 28 day course of treatment, sometimes extending outside of the conservative window period of 6 months. Antibody tests may also yield false negative results in patients with X-linked agammaglobulinemia; other diagnostic tests should be used in such patients.

Three instances of delayed HIV seroconversion occurring in health-care workers have been reported; in these instances, the health-care workers tested negative for HIV antibodies greater than 6 months postexposure but were seropositive within 12 months after the exposure.DNA sequencing confirmed the source of infection in one instance. Two of the delayed seroconversions were associated with simultaneous exposure to hepatitis C virus (HCV). In one case, co-infection was associated with a rapidly fatal HCV disease course; however, it is not known whether HCV directly influences the risk for or course of HIV infection or is a marker for other exposure-related factors.

Tests selected to screen donor blood and tissue must provide a high degree of confidence that HIV is not present (that is, a high sensitivity). A combination of antibody, antigen and nucleic acid tests are used by blood banks in Western countries. The World Health Organization estimated that, as of 2000, inadequate blood screening had resulted in 1 million new HIV infections worldwide.

In the USA, since 1985, all blood donations are screened with an ELISA test for HIV-1 and HIV-2, as well as a nucleic acid test. These diagnostic tests are combined with careful donor selection. As of 2001[update], the risk of transfusion-acquired HIV in the U.S. was approximately one in 2.5 million for each transfusion.

Now,there is the best medicine,that was discovered,anti-HIV. And Pharmaceutical Intermediates<a href=http://www.timepharm.com/category/pharmaceutical-intermediates-2087-d2ac/1>Pharmaceutical Intermediates<a/> is the best element.

FIGHT FOR HEALTH, THINKING GOES FIRST
Everyday, when we open the television, countless of drug advertisings for “affluenza” begin to flood our eyes. Many people feel disgust to the advertisings and scared the disease, because they know that such a lot people nearing are suffering with this disease but could not do anything about it. It just like a child lost in the forest that does not know which path could lead him out.

In my mind, difficult things are as enemies on the battlefield. The most you want to beat them, the first you have do, is to have a detailed recognition to them, then you could choose a way to “get rid of them”.

First of all, we must to know what is hyperlipemia? The reason to cause it and the result it will cause. Human body is a modern metropolis, dominated by intricate and complicated transport lines – the blood vessel – each moment. Because the body used them to transport oxygen and nutritive materials to different organs, and to transport CO2 and some “trash” out. It is well known that nourishment, such as cholesterol and vitamin D, are necessary and useful for our body and brain, but this does not mean the more we take in, the smarter and healthier we will be. Things always have two sides that opposite to each other, and right will turn to wrong if it is done too much to brake the line. nourishment are these things which were called “wealthy food ”. If they are took in but not completely ingested by your body, the superfluous will stay and accumulate on your inner artery wall to form plaque . LDL (low-density lipoprotein) are believed the worst aliment when it was take in excess. It will adhere on the inner artery wall and accumulate. The artery will be blocked if the acumulated LDL is too much, and bad things will come. For example, If an obstruction occurs in the coronary arteries, it could result in a heart attack. And, if an obstruction occurs in the arteries of the brain, it could lead to stroke.

Two ways could be chose for reducing the LDL’s percentage in the body. First and main way is to take in food with smaller fat or small fat food to reduce fat’s quantity; the other is use something (always drugs) to consume the superfluous fat (include LDL). We all believe believe the most useful method is to form a good diet habit, but an effective drug used in auxiliary can not only relieve the the patient’s pain, but also give the courage to beat hyperlipemia.

Lipid-lowering drugs mainly include statins, fibrates, nicotinic acid and bile acid sequestrants. They have functions on different kind of fat, but the purpose is same – to reduce the fat. For example, fibrates are more active in reducing triglyceride than reducing cholesterol, while HMG-Co A (3-hydroxy-3-methylglutary coenzyme A) are main active on reducing cholesterol with high effects. Recently, a compound medicine of Ezetimibe was released to used as reducing cholesterol drug. (It is honored that one of our product — 2-Chloro-4,6-dimethoxy-1,3,5-triazine — could be used as one of its intermediates. A research from Britain indicates that this drug has higher effects on reducing cholesterol than others.

Progress in culture and technology let us pay closer attention to health. We want to fight for health along with all Pharmaceutical corporates to make life more beautiful and colorful.

Reference from: Time-Chem http://www.timepharm.com/news/item_668.html

Reprinted from: Pharmaceutical Intermediates

Chemical companies will increase their capital spending 8.6% to nearly $8.8 billion, according to an early February survey of 17 companies by Chemical & Engineering News. For 2007, C&EN reports that the actual capital spending of the 18 companies surveyed increased by 13.2% to $8.1 billion. These companies include Dawnrays Pharmaceutical (Holdings) Ltd., Suzhou Time-chem Technologies, Nanjing Source Chemical Co., Ltd., and so on. Survey results from 14 companies indicate R&D spending will grow 6.0% to $2.8 billion in 2008. The budgets for 2008 indicate that 71.5% of funds will go towards capital projects and 28.5% towards R&D. The American Chemistry Council (ACC) anticipates that 2008 capital spending for basic and specialty chemical companies will increase by 6.3% and R&D spending will increase by 4.4%. The ACC also reports that over the long term, its members will reduce the US share of their total capital spending budgets from 62% in 2006 to 48% in 2011. The Synthetic Organic Chemical Manufacturers also released a survey of its members, with 75% reporting that they would increase their R&D investment between 2% and 10%, with the mean investment being 8.6% of sales. Of those surveyed, 38% claimed that they are very likely or somewhat likely to increase their capital spending for 2008, with a mean investment of 10.8% of sales.

With an accelerated development of global chemical industry, China’s chemical industry, as an important element of the global industry, also enjoys a rapid development – Since 2008, with the fast growth of domestic economy, the importance of chemical industry becomes more and more apparent. We should, however, still be fully aware that by the year of 2009, the impact of global financial crisis on China will inevitably be intensified as a result of China’s integration with the global economy. Chemical will be the most seriously affected industry as one of the leading industries in the crisis. However In China, we all know Chinese people will usually change difficulties to motivation. Especially, Suzhou Time-Chem Technologies Co.,Ltd continues being focused on improving products’ quality, strengthening R&D, developing good corporate culture, and maintaining the best team spirit. Every employee is full of confidence to pursue a common development with the company well in 2009, a specific year.